Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma

Abstract: Use of brentuximab vedotin (BV) and PD-1 monoclonal antibodies (mAbs) before autologous stem cell transplantation (ASCT) could impact the benefit of post-ASCT BV maintenance in relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). We identified 1091 patients with R/R cHL who underwent...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ayo S. Falade, Robert Redd, Sanjal H. Desai, Alison J. Moskowitz, Harsh Shah, Susan M. Geyer, Nivetha Ganesan, Tiffany Chang, Tamer Othman, Gunjan L. Shah, Adrienne Nedved, Urshila Durani, Lay She Ng, Kelsey Baron, Shin Yeu Ong, Kevin Yoon, Stephen M. Ansell, Siddharth Iyengar, Ivana Micallef, Robert Stuver, Alex F. Herrera, Matthew Mei, Philippe Armand, Reid W. Merryman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-06-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952926002521
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!